Clinical Trial

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Study acronym: STEP
Completed Phase 3
View on ClinicalTrials.gov →
Summary
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to maintain asthma control in Chinese patients.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-14
critical Primary endpoint(s) modified 2026-08-14
Trial Details
NCT Number NCT06465485
Lead Sponsor AstraZeneca
Conditions Severe Eosinophilic Asthma
Enrollment 504 participants
Start Date 2024-02-28
Primary Completion 2026-05-13 (estimated)
Study Completion 2026-05-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-13